Brought to you by:
Data and device tweaks herald ‘practice-changing’ future for bioabsorbable scaffolds
Pending the results of several trials and “iterative changes” to device design, bioabsorbable scaffolds are set to change the treatment paradigm for lower extremity peripheral arterial disease (PAD) within the next decade. So concluded Eric Secemsky (Beth Israel Deaconess Medical…
Cagent Vascular initiates the Serranator POINT FORCE observational registry
Cagent Vascular has announced the start of the POINT FORCE registry, a postmarket clinical follow-up study of the Serranator percutaneous transluminal angioplasty (PTA) serration balloon catheter. This prospective, multicentre, single-arm study will enrol a minimum of 500 patients at up…
SVS gets moving on PAD-related grant
All those steps logged during the SVS Foundation’s exercise challenge in September will help the Foundation—and researchers—take new steps to unlock new treatments for peripheral artery disease (PAD). The foundation’s Vascular Health Step Challenge, during National PAD Awareness Month, raised…
Study finds adverse outcomes after decreased use of paclitaxel-coated devices
A recent analysis of over 270,000 Medicare fee-for-service beneficiaries has found an increase in adverse outcomes and death after a US Food and Drug Administration (FDA) warning led to decreased use of paclitaxel-coated devices for peripheral revascularisation procedures. Writing in…
Pioneering Florida limb preservation program laser-focuses on evidence-based, customized care for PAD
This advertorial is sponsored by Tampa General Hospital. As the prevalence of peripheral arterial disease (PAD) continues to climb across the U.S. and globally, a pioneering limb preservation program in south Florida is sharpening its resolve to provide cutting-edge treatment…
CPVI course: Learning the latest intricate skills and techniques to treat complex PAD
Vascular Specialist attended the SVS Complex Peripheral Vascular Interventions (CPVI) Skills Course and spoke with participants about the hands-on learning experience designed for vascular surgeons and specialists at all stages of their careers. Over two days (Sept. 28–29), participants learned…
BIO-OSCAR SOC trial examines standard of care in PAD treatment
Biotronik today announced that it has concluded the BIO-OSCAR SOC study evaluating the baseline against which to measure the Oscar multifunctional catheter in treating complex peripheral arterial disease (PAD). The outcomes were presented at the Paris Vascular Insights (PVI) course 2024…
Service: Giving back
Pioneering American Venous Forum (AVF) and Eastern Vascular Society (EVS) efforts aimed at breaking down barriers to care and educating patients in economically challenged communities on vascular disease have yielded early gains over the first two events staged this year.…
BEST-CLI: Trial results endure in analysis of patients who presented with diabetes
Diabetes affects approximately 70% of patients with chronic limb-threatening ischemia (CLTI) and is associated with more severe presentation, driven mostly by higher rates of wounds and infections, according to a recently presented retrospective analysis of BEST-CLI randomized controlled trial data.…
Research suggests arm vein is the best alternative bypass conduit to GSV in patients with CLTI
A new analysis has found arm vein to be the most suitable alternative conduit to great saphenous vein (GSV) in chronic limb-threatening ischemia (CLTI) patients, particularly in below-knee bypass targets. Prosthetic grafts also represent an adequate option, the researchers add,…